{"name":"Fundação Pró Rim","slug":"funda-o-pr-rim","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Everolimus+Tacrolimus+Prednisone","genericName":"Everolimus+Tacrolimus+Prednisone","slug":"everolimus-tacrolimus-prednisone","indication":"Prevention of organ rejection in renal transplant recipients","status":"marketed"},{"name":"Mycophenolate+Tacrolimus+Prednisone","genericName":"Mycophenolate+Tacrolimus+Prednisone","slug":"mycophenolate-tacrolimus-prednisone","indication":"Prevention of organ rejection in renal transplant recipients","status":"marketed"}]}],"pipeline":[{"name":"Everolimus+Tacrolimus+Prednisone","genericName":"Everolimus+Tacrolimus+Prednisone","slug":"everolimus-tacrolimus-prednisone","phase":"marketed","mechanism":"This triple immunosuppressive regimen inhibits T-cell proliferation and activation to prevent organ rejection after transplantation.","indications":["Prevention of organ rejection in renal transplant recipients"],"catalyst":""},{"name":"Mycophenolate+Tacrolimus+Prednisone","genericName":"Mycophenolate+Tacrolimus+Prednisone","slug":"mycophenolate-tacrolimus-prednisone","phase":"marketed","mechanism":"This triple immunosuppressive regimen suppresses T-cell proliferation and activation to prevent organ rejection after transplantation.","indications":["Prevention of organ rejection in renal transplant recipients"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}